These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 23583813

  • 1. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R, Taylor T, Moore MR, Active Bacterial Core Surveillance Team.
    Vaccine; 2013 May 24; 31(22):2572-7. PubMed ID: 23583813
    [Abstract] [Full Text] [Related]

  • 2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN.
    Vaccine; 2019 Jul 26; 37(32):4491-4498. PubMed ID: 31272872
    [Abstract] [Full Text] [Related]

  • 5. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP.
    Pediatr Infect Dis J; 2013 Feb 26; 32(2):e45-53. PubMed ID: 23080290
    [Abstract] [Full Text] [Related]

  • 6. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 7. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 8. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.
    Vaccine; 2014 Jun 05; 32(27):3452-9. PubMed ID: 24690148
    [Abstract] [Full Text] [Related]

  • 9. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E.
    Lancet Infect Dis; 2015 May 05; 15(5):535-43. PubMed ID: 25801458
    [Abstract] [Full Text] [Related]

  • 10. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG.
    Lancet Infect Dis; 2015 Mar 05; 15(3):301-9. PubMed ID: 25656600
    [Abstract] [Full Text] [Related]

  • 11. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB.
    JAMA Pediatr; 2015 Jul 05; 169(7):646-52. PubMed ID: 25938798
    [Abstract] [Full Text] [Related]

  • 12. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, Maor Y, Chazan B, Schindler Y, Dagan R, IAIPD group.
    Vaccine; 2017 Apr 25; 35(18):2449-2456. PubMed ID: 28342668
    [Abstract] [Full Text] [Related]

  • 13. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ.
    BMC Infect Dis; 2015 Oct 14; 15():419. PubMed ID: 26468008
    [Abstract] [Full Text] [Related]

  • 14. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
    Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, Holtzman C, Zansky SM, Thomas A, Baumbach J, Harrison LH, Farley MM, Beall B, McGee L, Gierke R, Pondo T, Kim L.
    Clin Infect Dis; 2016 May 01; 62(9):1119-25. PubMed ID: 26908787
    [Abstract] [Full Text] [Related]

  • 15. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Mar 12; 59(9):253-7. PubMed ID: 20224541
    [Abstract] [Full Text] [Related]

  • 16. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, Saitoh A, Oishi T, Hosoya M, Togashi T, Oishi K, Ihara T.
    Vaccine; 2015 Nov 09; 33(45):6054-60. PubMed ID: 26235372
    [Abstract] [Full Text] [Related]

  • 17. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ, McIntosh ED, Reinert RR.
    Int J Infect Dis; 2010 Mar 09; 14(3):e197-209. PubMed ID: 19700359
    [Abstract] [Full Text] [Related]

  • 18. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E, Albert MJ.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [Abstract] [Full Text] [Related]

  • 19. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.
    Pediatr Infect Dis J; 2013 Jun 31; 32(6):604-9. PubMed ID: 23348816
    [Abstract] [Full Text] [Related]

  • 20. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.